# A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

> **NCT03416374** · PHASE4 · COMPLETED · sponsor: **Takeda** · enrollment: 45 (actual)

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Bortezomib
- **DRUG:** Carfilzomib
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03416374
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-18
- **Primary completion:** 2021-05-28
- **Final completion:** 2021-05-28
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03416374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03416374, "A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03416374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*